% along with 3-5% rising income per head resulting from the launch of new buildings and the enablement of medical excellence centers as planned. Unit : Million Baht Revenues Structure Six month period 2018

issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged share capital (the “Share Purchase”) at the price of INR 36 per share. The Company would

by its indirect subsidiary Indorama Netherlands B.V. (“INBV”) of 83,000,000 newly issued shares in Indo Rama Synthetics (India) Limited (“IRSL”), equaling to approximately 31.79% of IRSL’s enlarged

or 22.90% over the same period of last year of which hospital revenues totally raised by 10.16% along with the enlarged customer base of Subsidiary (AMARC) showing 15.67% of revenues’ growth. In

year, the Company has not yet earned income from Excellence Center (New Building) planned to official grand opening in the following year of February 2018) along with the enlarged customer base of the

attributable to consistent orders from present customer and new customer. 1. Cost of sales and gross profit The Company’s cost of sales in year 2018 amounted to Baht 256.50 million, rising year-on-year by Baht

of sales 2,539.53 million baht (83.00% when compared to sales), net profit of 125.73 million baht, decreased 88.96 million baht or 70.75 percent because commodity prices are rising, and the market is

). Net profit was Baht 93.80 million, a decrease of Baht 93.80 million from the same period of last year. Baht 56.25 million or a decrease of 59.96% because commodity prices are rising. And the market is

) (1.6) (5.5) -349% Earnings per share (THB/share) (0.01) (0.00) (0.01) -349% ⚫ Referring to rising in market price of rice (raw material), COGs/revenue ratio of Q1/2018 are at 84%, comparing to 82% of

) (1.6) (5.5) -349% Earnings per share (THB/share) (0.01) (0.00) (0.01) - ⚫ Referring to rising in market price of rice (raw material), COGs/revenue ratio of Q1/2018 are at 84%, comparing to 82% of same